Literature DB >> 15259505

TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma.

Dawn Sears1, Richard A Erickson, Lubna Sayage-Rabie, Martha C Escobar.   

Abstract

Our purpose was to determine if fine-needle aspirates of pancreatic adenocarcinoma would produce material amenable to tumor marker staining and to correlate the expression of TGF-beta and p53 with patient and tumor data. One hundred twenty specimens were analyzed. TGF-beta was positive in 26% of cases and had no correlation with patient's age, sex, survival, stage, grade, or size. p53 was positive in 22% of the cases and correlated only with grade 1 tumors. Expression of TGF-beta and p53 can be tested on preserved cytologic specimens. This is the largest study to date correlating TGF-beta and p53 expression in pancreatic adenocarcinoma and patient demographics, prognosis, and tumor attributes. This is also the first study that did not select for surgical candidates. TGF-beta expression does not appear to have prognostic significance in pancreatic cancer. p53 was more common in well-differentiated tumors and may be an early mutation lost in more poorly differentiated tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259505     DOI: 10.1023/b:ddas.0000030095.71501.04

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells.

Authors:  M Kusumoto; T Ogawa; K Mizumoto; H Ueno; H Niiyama; N Sato; M Nakamura; M Tanaka
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

2.  Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.

Authors:  Mansoor M Ahmed; Rachael A Alcock; Damodaran Chendil; Swatee Dey; Anindita Das; Kolaparthi Venkatasubbarao; Mohammed Mohiuddin; LuZhe Sun; William E Strodel; James W Freeman
Journal:  J Biol Chem       Date:  2001-11-01       Impact factor: 5.157

3.  Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.

Authors:  Y Nio; M Dong; C Iguchi; K Yamasawa; T Toga; M Itakura; K Tamura
Journal:  J Surg Oncol       Date:  2001-03       Impact factor: 3.454

4.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

5.  Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.

Authors:  P Ghaneh; W Greenhalf; M Humphreys; D Wilson; L Zumstein; N R Lemoine; J P Neoptolemos
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

6.  Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Authors:  P S Moore; B Sipos; S Orlandini; C Sorio; F X Real; N R Lemoine; T Gress; C Bassi; G Klöppel; H Kalthoff; H Ungefroren; M Löhr; A Scarpa
Journal:  Virchows Arch       Date:  2001-12       Impact factor: 4.064

7.  Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

Authors:  C Sun; T Yamato; T Furukawa; Y Ohnishi; H Kijima; A Horii
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

Review 8.  Tumor suppressor activity of the TGF-beta pathway in human cancers.

Authors:  S D Markowitz; A B Roberts
Journal:  Cytokine Growth Factor Rev       Date:  1996-06       Impact factor: 7.638

9.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

10.  Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.

Authors:  E Mercadé; M Cascalló; M Carrió; J Calbó; A Gómez-Treviño; C Fillat; A M Gómez-Foix; A Mazo
Journal:  Ann Oncol       Date:  2001-03       Impact factor: 32.976

View more
  2 in total

1.  Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics.

Authors:  Nil Culhaci; Ozgul Sagol; Sedat Karademir; Huseyin Astarcioglu; Ibrahim Astarcioglu; Mujde Soyturk; Ilhan Oztop; Funda Obuz
Journal:  BMC Cancer       Date:  2005-08-08       Impact factor: 4.430

Review 2.  Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Authors:  Yandiswa Yolanda Yako; Deirdré Kruger; Martin Smith; Martin Brand
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.